Skip to main content
  • New Data Highlight Promising Angiographic and Safety Profile of BIOTRONIK’s Third Generation Resorbable Magnesium Scaffold

    Six-Month-Results from the BIOMAG-I Clinical Study Including Intravascular Imaging Data Were Presented at CRT 2023

    Prof. Michael Haude, BIOMAG-I Coordinating Clinical Investigator, presented the latest results of the BIOMAG-I clinical study at the Cardiovascular Research Technologies (CRT) meeting.1 At six months the angiographic and clinical data showed a low in-scaffold late lumen loss (LLL) rate and a good safety profile with no scaffold thrombosis. A low proportion of mal-apposed struts after implantation was observed, at six months struts were no longer discernable. The intravascular imaging documented a preservation of the scaffold area with a low mean neointimal area.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details